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Available online xxxxPurpose: This was a phase-II, randomized, double-blind (DB), placebo-controlled study aimed to evaluate
neurocognitive effects of eslicarbazepine acetate (ESL) as adjunctive therapy in pediatric patients with refractory
focal-onset seizures (FOS).
Methods: Children (6–16 years old) with FOS were randomized (2:1) to ESL or placebo. Treatment started at
10 mg/kg/day, was up-titrated up to 30mg/kg/day (target dose), andmaintained for 8 weeks, followed by one-
year open-label follow-up. The primary endpoint was change from baseline to the end of maintenance period in
the composite Power of Attention assessedwith the CognitiveDrug Research (CDR) system. Behavioral and emo-
tional functioning and quality of life (QOL), secondary endpoints, were assessed with Child Health
Questionnaire-Parent Form 50 (CHQ-PF50), Child Behavior Checklist (CBCL), and Raven's Standard Progressive
Matrices (SPM). Efﬁcacy was evaluated through changes in standardized seizure frequency (SF), responder
rate, and proportion of seizure-free patients. Safety was evaluated by the incidence of treatment-emergent
adverse events (TEAEs).
Results: One hundred and twenty-three patients were randomized. A noninferiority analysis failed to reject the
null hypothesis that the change from baseline in the Power of Attention score in the ESL group was at least
121 ms inferior to the placebo group for all age groups. The CDR scores showed no differences between placebo
and ESL in Power of Attention (1868.0 vs 1759.5), Continuity of Attention (1.136 vs−1.786), Quality ofWorking
Memory (−0.023 vs−0.024), and Speed of Memory (−263.4 vs−249.6). Nonsigniﬁcant differences between
placebo and ESL were seen for CHQ-PF50, CBCL scores, and Raven's SPM. EpisodicMemory Index showed signif-
icant negative effect on ESL. Efﬁcacy results favored the ESL group (SF least square [LS] means 1.98 vs 4.29). The
TEAEs had a similar incidence between treatment groups (41.0% vs 47.5%).
Conclusions: Overall ESL did not produce statistically signiﬁcant effects on neurocognitive and behavioral
functioning in patients with epilepsy aged 6 to 16 years. Additionally, ESL was effective in reducing seizure
frequency and was well-tolerated.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Seizures1. Introduction
Worldwide, epilepsy is estimated to affect over 50million people [1],
with children and adolescents being disproportionally impacted by this
neurological condition [2–4]. Antiepileptic drugs (AEDs) can be used to
successfully treat up to 70% of the affected children and adults [1].
Despite combination therapy, a large proportion of patients continued Development, BIAL, A Av. da
ortugal.
ilva).
. This is an open access article underto have seizures, and among children, 25% remain refractory to treat-
ment [5]. Adverse effects (AEs) caused by antiepileptic drugs are
major contributors for treatment failure [6], leading to low treatment
adherence [7,8] or discontinuation [8,9]. Epilepsy is often accompanied
by impairment of cognitive functions [10], and in children, it is linked to
attention, internalization, and thought difﬁculties that lead to poor
psychosocial outcomes in adulthood [11]. The underlying causes of
these problems are often challenging to precisely identify, but factors
such as the etiology, developmental problems of the disease, and
adverse effects of antiepileptic treatment may all play a role [12,13].
The most common cognitive effects associated with chronic use ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lance, and attention [14]. Even thoughmany pediatric studies reporting
cognitive effects of AEDs have been reviewed as inconclusive [15],
the therapeutic beneﬁts of AEDs may largely outweigh the negative
cognitive effects. This is of particular concern in children given the
potential to negatively impact learning, social behavior, and school
performance [15]. The risk of cognitive effects also highlights the need
for appropriately designed prospective studies, based on thorough and
well validated tools, to evaluate the effects of AEDson cognitive function
in children and to enable better comparisons across studies [16].
Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug
(AED) [17,18] that has been approved by the European Medicines
Agency (EMA), Food and Drug Administration (FDA), and Health
Canada as adjunctive therapy in adults with focal-onset seizures
(FOS), with or without secondary generalization. Later, both EMA- and
FDA-approved ESL for monotherapy in the same population of patients;
ESL has also been approved by EMA as adjunctive therapy in children
aged above 6 years old with FOS. More recently, ESL received FDA
approval for expanded indication to treat FOS in children and adoles-
cents 4 years of age and older.
The current study was aimed at evaluating the effect of adjunctive
therapy with ESL on cognitive function in children and adolescents
aged 6 to 16 years old with refractory FOS. Efﬁcacy and safety of ESL
treatment in this age group are also addressed.
2. Patients and methods
This was a multicenter phase II, randomized, double-blind (DB),
placebo-controlled, parallel study to evaluate the cognitive effects of ESL
as adjunctive therapy in children with refractory FOS (NCT01527513).
The study was conducted in 4 countries (Italy [18 patients], Poland
[18 patients], Russia [47 patients], and Ukraine [40 patients]). Children
(6–16 years old), diagnosed with epilepsy for ≥12 months prior to
enrolment, with at least 2 epileptic FOS (≥4 in the month before enrol-
ment), receiving 1–2 AEDs (except oxcarbazepine), and intelligence
quotient (IQ) ≥70, were randomized (2:1) to ESL or placebo.
Part I consisted of an observational baseline period of 4 weeks,
followed by a double-blind period of 12 weeks, comprising a 4-week
up-titration period from 10 mg/kg/day for 2 weeks followed by
20 mg/kg/day for 2 weeks (to a maximum of 1200 mg/day). This
was followed by an 8-week double-blind maintenance period at
30 mg/kg/day (or to a maximum of 1200 mg/day) if no intolerable
AEs occurred at 20 mg/kg/day; if intolerable AEs occurred, the patient
was down-titrated to the previous dose or discontinued. Patients
down-titrated to 10 mg/kg/day during titration period received this
dose for the 8-week maintenance period. There was a tapering-off
period of up to 4 weeks where study treatment was tapered off in
10mg/kg/day steps, and then, therewas an additional 4-week observa-
tional follow-up period (Fig. 1). Treatment was given in 200-mg
divisible tablets. The individual calculated dose was rounded to the
nearest 100 mg. Study treatments were provided as 200-mg tablets,
and doses were rounded to the nearest 100 mg (half tablet).
Part II consisted of a one-year, open-label, uncontrolled period
which started after completion of the last 2 weeks, 10 mg/kg/day
down-titration step in Part I (Fig. 1). All patients who entered this
period initially received a dose of 10 mg/kg/day ESL, but this dose was
titrated by the investigator according to clinical response, with a dose
range from 10 to 30 mg/kg/day (maximum allowed dose of 1200 mg
once daily (QD)). Doses were rounded to the nearest 100-mg unit.
Half tablets could be used for dosage adjustment, if necessary (tablets
were scored). Down-titration was allowed according to clinical re-
sponse or in case of intolerable AEs, as often as needed. As much as pos-
sible, concomitant AED therapy (1 or 2 AEDs) was kept stable
throughout Part II under the direction of the patient's physician. Patients
entering the one-year open-label extension attended the study clinic for
six scheduled visits during Part II for ongoing safety monitoring andperformance of study assessments. At the end of Part II, patients either
entered a tapering-off/follow-up period or a further period of open-
label treatment with ESL (Part III). For patients who completed Part II
and did not enter the additional two-year open-label extension, a
poststudy visit (PSV) was performed approximately 4 weeks after
study treatment was tapered off.
The Cognitive Drug Research (CDR) test battery [19,20] was used
to assess changes in cognitive function. The test is designed to cover
attention (focused and vigilant), working and episodic memory, and
information processing/psychomotor speed, and has been validated in
pediatric patients receiving AEDs [20]. An Episodic Memory Index (SI)
was created, taking the Word Recognition Sensitivity Index (DRECSI)
for children aged 9 to 16 years and the Picture Recognition Sensitivity
Index (DPICSI) for children aged 6 to 8 years. Global cognitive skills
were evaluated using the Raven's Standard Progressive Matrices
(SPM) test [21–24] for children which consists in a series of short, non-
verbal reasoning problems, based on visual spatial tasks that are used to
assess intelligence in persons from age 6 to adulthood, independently of
their cultural level. The test is composed of a total of 60 items presented
in 5 sets (A–E), with 12 items per set. Social competence was assessed
using the CBCL 6–18, which assesses child life function, and provides 2
major summary scores as follows: competence and problem behaviors.
It is a parent-rated questionnaire for children aged 6–18 years old. In
this study, only the competence score was evaluated as a measure of
the child's social behavior and competence. Abnormal competence
scores have been previously reported for children with epilepsy [25].
The quality of life (QOL) was evaluated using the Child Health
Questionnaire-Parent Form 50 (CHQ-PF50), a parent-rated question-
naire to assess the child's health, well-being, and the impact of illness
on life function that was designed and normalized for children 5–
18 years old. The CHQ-PF50 provides two weighted and standardized
summary scores for physical and psychosocial health (CHQ summary
scores). The physical health summary score measures the child's
general health, pain, and limitations in physical and social activities
due to health. The psychosocial health summary score measures the
child's self-esteem,mental health, and the impact of the illness on phys-
ical and social activities. Efﬁcacy was evaluated by relative reduction in
standardized seizure frequency (SSF; seizure frequency per 4 weeks),
proportion of responders (≥50% SSF reduction), and proportion of
seizure-free patients (100% seizure reduction) from baseline. Safety
was evaluated by the incidence of treatment-emergent adverse events
(TEAEs).
Sample size was calculated for a noninferiority study comparing the
Power of Attention following treatment with ESL as add-on therapy
with the Power of Attention in patients on placebo. Assuming a SD
of 202.3 for the Power of Attention score, a noninferiority limit of
121 ms, and a one-tailed test at the 0.025 signiﬁcance level, a total of
102 patients in the Cognitive per-protocol (PP) population would
provide 80% power to reject the null hypothesis that the mean increase
from baseline Power of Attention was at least 121 ms smaller in the
placebo group than in the ESL group versus the alternative hypothesis
that any advantage in the placebo group was less than in the inferiority
limit [20]. Allowing for premature discontinuations and/ormajor proto-
col violations (and hence exclusion from the Cognitive PP population), a
total of 117 patients were to be randomized (39 patients in the placebo
group and 78 patients in the ESL group).
The study was approved by an ethics committee. Written informed
consent was obtained from parent/legal representative and written
assent was obtained from the patient.
2.1. Statistical analysis
The primary endpoint was change from baseline to the end of main-
tenance period in the composite Power of Attention (sum of the reac-
tion time measures from the attentional tasks) measured with the
CDR to assess information processing speed and attention/psychomotor
Fig. 1.Dose schedule and study design (Part I and II). Part I consisted of an observational baseline period of 4 weeks, followed by a double-blind period of 12weeks, comprising a 4-week
up-titration period from 10mg/kg/day for 2 weeks followed by 20mg/kg/day for 2 weeks (to a maximum of 1200mg/day). Part II consisted of one-year, open-label, uncontrolled period
which started after completion of the last 2 weeks, 10 mg/kg/day down-titration step in Part I all patients who entered this period initially received a dose of 10 mg/kg/day ESL, but this
dose was titrated by the investigator according to clinical response, with a dose range from 10 to 30mg/kg/day (maximumallowed dose of 1200mgQD). Abbreviations: FU= follow-up;
PSV = poststudy visit; TP = tapering-off; V = Visit. For those patients down-titrated from 30mg/kg/day due to intolerable AEs (a) For those patients down-titrated from 20mg/kg/day
due to intolerable AEs during the titration period (b). Note: Randomization occurred at V2. At the last double-blind visit in Part I (V7 or TP), patients had the option to enter a one-year
extension with open-label treatment with ESL, or to be discontinued and have a FU visit.
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effects of treatment in composite Power of Attention with treatment
and country as ﬁxed effects and baseline Power of Attention score,
sex, and age as covariates. If treatment-by-sex or treatment-by-
country interaction was statistically signiﬁcant at the 10% level
(P ≤ 0.10), then a subgroup analysis (descriptive statistics and
ANCOVA analyses) of the primary cognitive variable by sex and/or
by country was to be performed. The least square means (LSMs) for
the change from baseline in each treatment group obtained from
the main ANCOVA model were presented together with their stan-
dard errors of the mean (SEM) and 95% conﬁdence intervals (CIs).
The differences between the LSM for the ESL versus placebo com-
parison were also presented together with the associated 95% CI and
P value. Noninferiority of ESL versus placebo was assessed by compar-
ing the 95% CI's upper bound of the difference of LSMs between treat-
ment groups (ESL–placebo) with 121 ms. If the side of the conﬁdence
interval indicating impairment was greater than 121 ms, the null
hypothesis was rejected. Other neurocognitive endpoints included as
secondary endpoints were change from baseline to the end of mainte-
nance period in the following CDR test battery: 1 — continuity of
attention (aggregate of the accuracy measures from the attentional
tasks); 2 — quality of working memory (combination of spatial and
numeric working memory sensitivity indices); 3 — quality of episodic
secondary memory (children ≥9 years only), 4 — word recognition(children ≥9 years only, deﬁned using the sensitivity index); 5 —
picture recognition (children b9 years only, deﬁned using the sensitiv-
ity index); 6 — speed of memory (sum of the speed measures from the
twoworkingmemory tasks (spatial and numeric); 7— the word recog-
nition task for children ≥9 years). Global cognitive skills, social compe-
tence, and quality-of-life endpoints included change from baseline to
the end of maintenance period in number of correct answers on the
Raven's SPM test, competence summary score from the Child Behavior
Checklist (CBCL) 6–18, and physical and psychosocial functioning
summary score from the Child Health Questionnaire (CHQ)-Parent
Form 50 (PF50). Secondary analysis of change from baseline in the
other scores of the CDR system, CHQ-PF50 and CBCL are presented
for the PP population, with the respective baseline scores as covariates.
The least square (LS) means for the change from baseline in each
treatment group were computed together with their 95% CIs. Differ-
ences in LS means for the comparison between ESL and placebo are
also presented together with their 95% CI and P value. For Raven's
SPM, since the assumption of normality was not conﬁrmed, a van
Elteren (Cochran–Mantel–Haenszel test with modiﬁed ridit scores)
nonparametric test was used. Efﬁcacy results are presented for the
intent-to-treat (ITT) population. Safety variables were analyzed
descriptively and performed for the safety set. If data weremissing or in-
complete, it was allocated to the previous available visit. Adverse effects
were coded using the Medical Dictionary for Regulatory Activities
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scriptively for the overall safety population. Statistical programming and
analyses were performed using SAS Versions 9.1.3 or 9.2.
3. Results
3.1. Analysis of populations
In this study, 123 pediatric patientswere randomized 2:1 to ESL (83)
or placebo (40) and stratiﬁed by the following age groups: 6–11 years
(36 ESL, 18 placebo) and 12–16 years (47 ESL, 22 placebo). Of these, 7
ESL patients prematurely discontinued during titration period, and
116 patients entered the double-blind maintenance period (76 ESL, 40
placebo). Of the 123 randomized patients, 91.1% completed the part I
of study (75 ESL, 37 placebo). All patients that completed Part I contin-
ued to the open-label extension. Of the 112 patients, 95 patients (84.8%)Fig. 2. Patient disposition. Abbreviations: DB= double-blind; ESL = eslicarbazepine acetate; O
who failed at the screening visit (V1) or at randomization (V2). Patients could havemore than
include patients who discontinued from either the titration or maintenance periods.completed the open-label extension period (33 patients, 89.2% with
previous double-blind placebo; 62 patients, 82.7% with previous
double-blind ESL). Of the 95 patients (84.8%) who completed the one-
year open-label extension period, 42 entered the two-year open-label
extension period (Fig. 2; Supplementary Table 1).
Demographic and baseline characteristics of the overall safety popu-
lation are presented in Table 1. Treatment groupswere balanced for age,
sex, and race. The mean age was 11.7 years, with a similar distribution
between age groups, and with a higher percentage of males in both
treatment groups (ESL, 56.6%; placebo, 65.0%). Body measurements
and average IQ scores were similar between treatment groups. The
most common concomitant AEDswere valproic acid (ESL 42.2%, placebo
57.5%), carbamazepine (ESL 31.3%, placebo 30.0%), and topiramate (ESL
24.1%, placebo 22.5%). Seizure frequency, standardized per 28 days
during the observational baseline period, was similar in both groups,
with median of 5.0 for ESL and 5.19 for placebo. Complex FOS was theL = open-label; V = visit. Notes: The total number of patients screened includes patients
one reason for discontinuation. Reasons for premature discontinuation from the DB period
Table 1
Patient's characteristics at baseline (safety set).
Placebo
(N = 40)
ESL
(N = 83)
Total
(N = 123)
Age (years), (SD) 11.6 (2.8) 11.8 (3.1) 11.7 (3.0)
Age group, n(%)
6–11 years 18 (45.0) 36 (43.4) 54 (43.9)
12–16 years 22 (55.0) 47 (56.6) 69 (56.1)
Gender, n (%)
Male 26 (65.0) 47 (56.6) 73 (59.3)
Female 14 (35.0) 36 (43.4) 50 (40.7)
Ethnicity, n (%)
Caucasian 39 (97.5) 83 (100.0) 122 (99.2)
Other 1 (2.5) 0 (0.0) 1 (0.8)
Body measurements, mean (SD)
Height (cm) 151.1 (17.4) 150.5 (17.4) 150.7 (17.3)
Weight (kg) 48.7 (18.4) 47.7 (18.8) 48.0 (18.6)
BMI (kg/m2) 20.80 (5.3) 20.24 (4.6) 20.43 (4.9)
Head circumference (cm) 53.6 (3.2) 54.0 (2.8) 53.9 (2.9)
IQ, mean (SD) 89.1 (12.8) 87.9 (16.1) 88.3 (15.1)
min–max 70–141 70–154 70–154
Number of AEDs at baseline, n (%)
1 19 (47.5) 44 (53.0) 63 (51.2)
2 18 (45.0) 37 (44.6) 55 (44.7)
AEDs continued onto DB period, n (%)
Valproic acid 23 (57.5) 35 (42.2) 58 (47.2)
Carbamazepine 12 (30.0) 26 (31.3) 38 (30.9)
Topiramate 9 (22.5) 20 (24.1) 29 (23.6)
Lamotrigine 4 (10.0) 14 (16.9) 18 (14.6)
Levetiracetam 3 (7.5) 12 (14.5) 15 (12.2)
Valproate sodium 1 (2.5) 4 (4.8) 5 (4.1)
Vigabatrin 1 (2.5) 2 (2.4) 3 (2.4)
Zonisamide 2 (5.0) 1 (1.2) 3 (2.4)
Acetazolamide 0 1 (1.2) 1 (0.8)
Ethosuximide 0 1 (1.2) 1 (0.8)
Lacosamide 1 (2.5) 0 1 (0.8)
Phenytoin 0 1 (1.2) 1 (0.8)
Primidone 1 (2.5) 0 1 (0.8)
Seizure frequency, median
(min; max)a
5.19 (1.6; 288.0) 5.00 (1.1; 152.4) –
Seizure type, n (%)b
Simple focal 11 (27.5) 21 (25.3) 32 (26.0)
Complex focal 32 (80.0) 54 (65.1) 86 (69.9)
Partial evolving to
secondarily generalized
11 (27.5) 29 (34.9) 40 (32.5)
a Standardized seizure frequency per 28 days during the 4-week observational baseline
period.
b During the 4 weeks prior to screening. Patients may have had more than one type of
seizure.
5S. Jóźwiak et al. / Epilepsy & Behavior 81 (2018) 1–11most frequently reported seizure type (ESL 65.1%, placebo 80.0%). Over-
all, ≥50% of patients were taking at least one concomitant AED at any
time point during the open-label period, with a higher proportion of
patients in the previous double-blind ESL group than in the placebo
group. No patients took ≥2 concomitant AEDs during the open-label
period.
Exposure during the double-blind period is deﬁned as the duration
of study drug treatment during the titration period + maintenance
period, which was scheduled to be 12 weeks (4-week titration and
8-week maintenance, total 84 days). The majority of patients started
the maintenance period at 30 mg/kg/day (92.5% placebo; 83.1% ESL);
however, between the 2 treatment groups the proportion of patients
was lower in the ESL group. This difference corresponds to the higher
proportion of patients in the ESL group who had an unscheduled dose
reduction during the titration period (2.5% placebo; 6.0% ESL). In the
ESL group, all of the unscheduled dose reductions during the titration
period were due to adverse reactions. The proportion of patients who
had an unscheduled dose reduction during the maintenance period
was low and similar between the treatment groups (10.0% placebo;9.6% ESL). During the one-year open-label period, the median values
of the dose of study drug were 14.82 mg/kg/day for Weeks 1 to 4;
29.58 mg/kg/day for Weeks 5 to 16; and 30.00 mg/kg/day for Weeks
17 to 28, Weeks 29 to 40, and Weeks ≥41. The exposure was similar
between patients who received placebo or ESL during the previous
double-blind period. Very few patients were on monotherapy with
ESL for some time in the course of the open-label period as follows:
6 patients, 3 from previous double-blind placebo (8.1%) and 3 from
previous double-blind ESL (4.0%).
3.2. Analysis of neurocognitive performance
Summary results from theneurocognitive CDR system are presented
in Table 2. At the end of the double-blind period, themean change from
baseline in composite Power of Attention was 95.6 for placebo and 62.4
for ESL. The difference in LSmean between placebo and ESLwas 33.2ms
for the overall age group, 25.4 ms for the age group 6–11 years old, and
20.1 ms for the age group 12–16 years old. As shown in Fig. 3, there
were essentially no differences between ESL and placebo (LSmean 95%
CI was +33 ms (−138, 204); P N 0.5) in what concerns Power of
Attention. However, noninferiority failed to reject the null hypothesis
because the 95% CI lower bound was below the noninferiority margin.
Patients entered a one-year open-label follow-up after the end of the
double-blind period. Over the year, the patients showed a mean
improvement in Power of Attention of 182 ms (235 ms for the 6 to
11 year old patients and 144 ms for the 12 to 16 year old patients). A
cross-sectional analysis on year-by-year change in Power of Attention
in a large sample of healthy individuals aged 6 to 17 years was
performed. From 6 to 16 years of age, the average yearly maturational
improvement in healthy children was 70 ms. Thus, in the present
study, the maturational development during the one-year open-label
follow-up clearly showed no evidence of falling behind what would be
expected for healthy children.
The score for Continuity of Attention also displayed no signiﬁcant
differences between placebo and ESL for the overall age group, the age
group 6–11 years old, and the age group 12–16 years old (Table 2).
The mean change from baseline was 1.1 for placebo and−1.8 for ESL
for a difference in LSmean of 2.9 (95% CI:−1.2; 7.0). A similar outcome
for the comparison between placebo and ESL was observed for the
Quality of Working Memory (LS mean− 0.023 in placebo vs−0.024
in ESL; P= 0.991) and Speed of Memory (LS mean difference− 13.8;
P= 0.959). In the Episodic Memory Index, there was a signiﬁcant neg-
ative effect on subjects treated with ESL increasing with time. At the
end of double-blind period, for the overall age groups, the LS mean for
ESL and placebo were −0.13 and 0.02 (P = 0.003), respectively; for
6–11 age group, the LS mean for ESL was 0.17 and for 0.05 placebo
(P = 0.027); age group 12–16 had LS means of −0.10 for ESL and
0.02 for placebo (P= 0.048). The mean score at the end of open-label
follow-up represents small decreases which were of irrelevant effect
sizes (all b0.01).
Results for the Physical Health and Psychosocial Health CHQ-PF50
summary scores are presented in Supplementary Table 2. At the end
of the double-blind period, the LS mean change from baseline was 2.5
for placebo and 3.2 for ESL, with a LS mean difference of 0.7 (95% CI:
−3.1; 4.4; P = 0.73) for the Physical Health summary score, for the
overall age groups. The difference between treatment groups varied
by age group with a LS mean difference of −1.49 points in the 6–11
age group (P = 0.44), and of 4.84 points (P = 0.10) in 12–16 age
group, favoring ESL. For the Psychosocial Health summary score, the
LS mean change from baseline was 2.5 for placebo and 3.2 for ESL,
with a LS mean difference of 0.7 (95% CI:−2.5; 4.0; P= 0.66), for the
overall age groups. Results were similar by age subgroup with statisti-
cally nonsigniﬁcant differences. The mean score at open-label baseline
was 43.6 (11.1). Ninety (83%) of these patients had CHQ Physical Health
Summary Score at week 52 or at early discontinuation from the open-
label phase. The mean score at the end of open-label follow-up
Table 2
LS mean (SEM) changes in scores of the CDR test system at the end of the double-blind period by age group and overall following placebo or eslicarbazepine acetate (ESL).
Placebo ESL Difference in LS means (95% CI) P valuea
Power of Attention
Overall age group 95.63 (70.57) 62.43 (55.49) 33.20 (−137.59, 203.99) 0.700
6–11 years 78.61 (151.22) 53.24 (119.09) 25.37 (−356.36, 407.11) 0.893
12–16 years 69.36 (66.90) 49.23 (51.11) 20.12 (−146.57, 186.83) 0.809
Continuity of Attention
Overall age group 1.136 (1.671) −1.786 (1.314) 2.921 (−1.154, 6.997) 0.158
6–11 years 4.885 (3.483) −1.655 (2.719) 6.541 (−2.241, 15.324) 0.139
12–16 years −0.742 (1.741) −0.847 (1.336) 0.1056 (−4.241, 4.453) 0.961
Quality of Working Memory
Overall age group −0.023 (0.056) −0.024 (0.044) 0.0008 (−0.1372, 0.1388) 0.991
6–11 years −0.036 (0.112) −0.029 (0.087) −0.0072 (−0.2909, 0.2763) 0.958
12–16 years −0.007 (0.057) 0.011 (0.043) −0.0186 (−0.1612, 0.1240) 0.794
Episodic Memory Index
Overall age group 0.0268 (0.040) −0.1270 (0.0322) 0.1537 (0.0529, 0.2546) 0.003⁎
6–11 years 0.0499 (0.0737) −0.1672 (0.0577) 0.2171 (0.0260, 0.4083) 0.027⁎
12–16 years 0.0219 (0.0474) −0.0984 (0.0364) 0.1203 (0.0013, 0.2393) 0.048⁎
Speed of Memory
Overall age group −263.4 (219.5) −249.6 (172.0) −13.8 (−545.7, 518.1) 0.959
6–11 years −614.8 (491.6) −281.8 (383.2) −333.0 (−1575.1909.1) 0.588
12–16 years −22.5 (175.5) −210.3 (134.6) 187.8 (−250.4, 625.9) 0.393
CI: Conﬁdence interval; EDB: end of double-blind; ITT: intent-to-treat; LS: least squares; PP: per-protocol; SE: standard error; SD: standard deviation.
Overall population (placebo, n = 36; ESL, n = 66); 6–11 years population (placebo, n = 16; ESL, n = 24); 12–16 years population (placebo, n = 20; ESL, n = 42).
a ANCOVAmodel analysis of change from baseline at EDB considering treatment as ﬁxed variable and age group, sex and country as covariates.
⁎ Signiﬁcantly different from placebo.
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little change (−0.1(10.5)) over this period in patients from both treat-
ment groups. Among patients originally randomized to ESL, scores im-
proved, on average, only by 1.1 (10.2) points between randomization
(double-blind baseline) and the end of the open-label phase.
In themean CBCL, scores at baselinewere similar between the study
arms (33.2 points for placebo and 30.8 for ESL), and at the end of
double-blind period, the LS mean difference between treatment groups
was−0.23 (95%CI:−2.5; 2.1; P=0.84). At baseline, therewere also no
statistically signiﬁcant differences between placebo and ESL in both age
groups (Supplementary Table 3). In part II, data were available from 97
patients as follows: 32 patients from the original placebo group and 65
from the original ESL group. The mean score at open-label baseline was
32.6 (8.4). Over three quarters (N = 76) of these patients had a CBCL
score of 33.5 at week 52 or early discontinuation, suggesting little
change over this period, and was similar between the initial treatment
groups, when considered separately.Fig. 3.Mean (95%CI) difference between placebo and ESL in the Power of Attention.Results to Raven's SPM are presented in number of correct answers
to the 60-item questionnaire (Supplementary Table 4). The median
number of correct answers at baseline was 39 for placebo and 37.5 for
the ESL group. At the end of double-blind period, median number of
correct answers was 40.5 for placebo and 41.0 for ESL. Since the
assumption of normality was not conﬁrmed for the ANCOVA analyses,
differences between groups were assessed using the nonparametric
van Elteren test. The difference in the median change between treat-
ment groups was 1.5 (P= 0.82). There were also no statistically signif-
icant differences between placebo and ESL in both age groups
(Supplementary Table 4). Open-label data for the analyses of the
Raven's SPM were available for 111 patients, 37 from the original pla-
cebo group and 74 from the original ESL group. At open-label baseline,
the median number of correct responses was 41.0, and was unchanged
at the end of this phase of the study. Patients originally randomized to
placebo started the open-label phase with a median score of 42.0,
compared with 40.5 for those in the ESL group. By week 52 (or at
early discontinuation), the median number of correct answers dropped
slightly to 40.0, whereas the ESL group improved to a median of 43.0.
3.3. Efﬁcacy results
Fig. 4A depicts the results of the standardized seizure frequency
during the maintenance period and titration + maintenance period
for the ITT population. The least square means for standardized seizure
frequency during themaintenance period alone (1.98 vs 4.29) and dur-
ing the titration+maintenance period (2.58 vs 4.63) were signiﬁcantly
lower in the ESL group than in placebo group (Fig. 4A). In the ITT popu-
lation, the median relative change in standardized seizure frequency
from baseline during the maintenance period was−31.6% in the pla-
cebo group and−51.7% in the ESL group (Fig. 4B). Considering the titra-
tion + maintenance period, similar results were observed where the
median relative change from baseline was −21.9% in the placebo
group and−47.9% in the ESL group. The differences between the treat-
ment groups with respect to relative change from baseline in standard-
ized seizure frequency during themaintenance period alone and during
the titration + maintenance period are statistically signiﬁcant based
on the nonparametric analyses (P b 0.001 each). The results of these
Fig. 4.Mean and 95%CI seizure frequency per 4 weeks (A), mean relative reduction in seizure frequency (B), mean relative change in seizure frequency (C) over the 8-week maintenance
and mean responder rate (i.e., percentage of patients with ≥50% reduction in seizure frequency) (D).
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were similar to the overall results. Results for the efﬁcacy PP population,
with median relative changes were from baseline of −30.7% and
−54.1% during the maintenance period alone and −20.9% and
−48.2% during the titration + maintenance period for the placebo
and ESL groups, respectively. Again, differences from placebo and ESL
are statistically signiﬁcant based on the nonparametric analyses
(P b 0.001 each). Results for the ITT population for patients who com-
pleted the tapering-off period are shown in Supplementary Table 5. The
results in this subset of patients indicate that there was no rebound
effect in seizure frequency. The results of these analyses in each of the
2 age groups (6 to 11 years and 12 to 16 years) were similar to the over-
all results (Supplementary Table 5).
All patients were categorized according to their percentage change
from baseline in standardized seizure frequency, in six categories rang-
ing from seizure-free (100% reduction) to exacerbation (≥25% increase),
as depicted in Fig. 4C. Two patients (5.0%) in the placebo group and 18(21.7%) in the ESL group, who completed the entire maintenance
period, achieved100% reduction of seizures.When the analysiswas lim-
ited to patients who had completed at least 4 weeks of treatment, the
ﬁgures remained the same. The difference between the treatment
groups with respect to the proportion of seizure-free patients during
the maintenance period was statistically signiﬁcant (P= 0.024). A mi-
nority of patients in both treatment groups showed exacerbation during
themaintenance period, as evidenced by an increase of ≥25% frombase-
line in standardized seizure frequency. The rates were similar between
the treatment groups (15.0% placebo and 14.5% ESL). The rates of reduc-
tion were similar between the placebo group and the ESL group for the
range of N75% to b100% reduction and ≥50% to ≤75% reduction. For the
range of 0% to b50% reduction, the trend reversed, with the rate higher
in the placebo group than in the ESL group. The difference between the
treatment groups with respect to the overall distribution of percentage
change from baseline in standardized seizure frequency during the
maintenance period was statistically signiﬁcant (P= 0.047).
Fig. 5.Mean (and SD) standardized seizure frequencyper 4weeks during thedouble-blind
and one-year open-label period (A) and standardized seizure reduction or exacerbation
during the one-year open-label period (B).
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the maintenance period was of 50.6% for ESL and 25.0% for placebo
(P = 0.009) (Fig. 4D). During the titration + maintenance period, the
percentage of responders was 27.5% in the placebo group and 48.2% in
ESL group (P=0.038). The overall seizure-free rate for patients that com-
pleted the maintenance period was higher for ESL (25.3%) than placebo
(5.0%) (Fig. 4C). During the maintenance period, the percentages of re-
sponders for children aged 6 to 11 years were 27.8% (placebo) and
55.6% (ESL) and for adolescents aged 12 to 16 yearswere 22.7% (placebo)
and 46.8% (ESL). Supplementary Table 5 summarizes the relative change
from baseline in standardized seizure frequency by study period, includ-
ing the titration, maintenance, titration +maintenance, and tapering-off
periods for themodiﬁed efﬁcacy ITT population by age group and overall.
Analysis of covariance was performed on the relative change from
baseline in standardized seizure frequency and the standardized seizure
frequency during the maintenance period and included the baseline
standardized seizure frequency as a covariate in the model, as well as
age group (stratiﬁcation variable) and sex as baseline covariates.
The treatment-by-age group and treatment-by-sex interactions were
investigated in separate ANCOVA models. In addition, other baseline
covariates (e.g., age at onset of epilepsy, number of AEDs ongoing at base-
line) and treatment-by-covariate interactions were also investigated
in the primary cognitive analyses. There were no statistically sig-
niﬁcant treatment-by-age group (n = 104; P = 0.927), treatment-by-
sex (n = 104, P = 0.962), or treatment-by-country (n = 104; P =
0.801) interactions in the analysis of standardized seizure frequency dur-
ing the maintenance period.
During the open-label period, the previous double-blind placebo
group experienced a decrease in standardized seizure frequency gradu-
ally becoming similar to the previous double-blind ESL group. Fig. 5A
depicts the mean standardized seizure frequency during the double-
blind and the one-year open-label period (Weeks 1 to 4, Weeks 5 to
16, Weeks 17 to 28, Weeks 29 to 40, and Weeks ≥41). Median
postbaseline standardized seizure frequencies were lower in the
previous double-blind ESL group compared with the placebo group at
most timepoints. The median relative change from baseline during the
one-year open-label period was−59.57% in the previous double-blind
placebo group and −65.47% in the previous double-blind ESL group.
During the open-label period, the percentage of responders increased
over time in both treatment groups, with consistently higher percent-
ages of responders who received previous double-blind ESL compared
with patientswho received previous double-blindplacebo, respectively,
as follows: Weeks 1 to 4 (56.0% vs. 51.4%), Weeks 5 to 16 (64.4% vs.
55.6%), Weeks 17 to 28 (67.6% vs. 54.5%), Weeks 29 to 40 (74.2% vs.
62.5%), Weeks ≥41 (75.4% vs. 65.6%). Overall, the percentage of
responders for children aged 6 to 11 years was 63.0% (previous
double-blind placebo, 50.0%; previous double-blind ESL, 70.0%), and
60.6% for adolescents aged 12 to 16 years (previous double-blind
placebo, 57.1%; previous double-blind ESL, 62.2%), which shows a
comparable effect in the 2 age groups.
In the open-label period, all patients were categorized according
to their percentage change from baseline in standardized seizure
frequency, in six categories ranging from seizure-free (100% reduction)
to exacerbation (≥25% increase) (Fig. 5B). The majority of patients
showed N50% reduction in seizure frequency, overall and in each
treatment group, as previously described. Within these responders,
the majority (32.1%) showed a reduction of N75% to b100%, with
comparable proportions between the two treatment groups (29.7% for
previous double-blind placebo and 33.3% for previous double-blind
ESL). Among the patients with reduction b50%, the previous double-
blind placebo group showed that the rate was higher for placebo.
3.4. Safety results
Safety results for this study have shown that TEAEs had a similar in-
cidence between ESL and placebo (41.0% vs 47.5%) in the double-blindpart; a brief summary of AEs overall and by age group is presented in
Supplementary Table 6. The TEAEswith an incidence of N3% of patients,
in either treatment group, in descending order by ESL group, by pre-
ferred term are presented in Table 3. The most commonly reported
TEAEs with an incidence of N3% of patients, in either treatment group,
were headache (9.6% in ESL vs 15.0% in placebo), somnolence (6.0% in
ESL vs 5.0% in placebo), and vomiting (6.0% in ESL vs 2.5% in placebo).
Most TEAEs were of mild or moderate intensity for both treatment
groups. Severe TEAEs occurred in nomore than 1 patient in either treat-
ment group. A total of 5 patients reported at least one serious TEAE,with
2 patients (5.0%) in the placebo group and 3 patients (3.6%) in the ESL
group. One patient (1.2%) in the ESL group experienced severe status
epilepticus, which was considered serious, possibly related to study
drug, and led to discontinuation of study treatment. The prevalence of
serious TEAEs was generally low (2 patients in placebo and 3 in ESL),
and no deaths occurred during the study. Five patients (6.0%) had
TEAEs that led to premature discontinuation, all of which occurred in
the ESL group. In the open-label part TEAEs that were more frequent
in the previous double-blind ESL group than in the placebo group
were respiratory tract infection, including viral (5.4% placebo; 9.4%
ESL) and nasopharyngitis (0 placebo; 4.0% ESL), but these were infre-
quent overall. The proportion of patients who reported headache was
higher in patients who received previous double-blind placebo (8.1%)
Table 3
Treatment-emergent adverse events with an incidence N3% of patients in by preferred
term (safety population).
Double-blind part
Placebo
(N = 40)
ESL
(N = 83)
Patients with any TEAE 19 (47.5) 34 (41.0)
Headache 6 (15.0) 8 (9.6)
Somnolence 2 (5.0) 5 (6)
Vomiting 1 (2.5) 5 (6)
Dermatitis allergic 0 4 (4.8)
Respiratory tract infection 2 (5) 4 (4.8)
Diplopia 0 3 (3.6)
Dizziness 1 (2.5) 3 (3.6)
Respiratory tract infection viral 0 3 (3.6)
Nausea 2 (5.0) 2 (2.4)
Pyrexia 2 (5.0) 1 (1.2)
Open-label part
Previous placebo
(N = 37)
Previous ESL
(N = 75)
Patients with any TEAE 17 (45.9) 28 (37.3)
Respiratory Tract Infection Viral 1 (2.7) 5 (6.7)
Headache 3 (8.1) 3 (4.0)
Vomiting 1 (2.7) 3 (4.0)
Pyrexia 1 (2.7) 3 (4.0)
Nasopharyngitis 0 3 (4.0)
Convulsion 2 (5.4) 2 (2.7)
Inﬂuenza 3 (8.1) 0
Head injury 2 (5.4) 0
Dizziness 2 (5.4) 0
Urticaria 2 (5.4) 0
Abbreviations: ESL = eslicarbazepine acetate; TEAE = treatment-emergent adverse
event.
Percentages are calculated based on the number of patients in the Safety population. Ad-
verse events are classed as treatment-emergent if they started on or after the date of ﬁrst
dose of study treatment. Adverse eventswith partial ormissing start dates are classiﬁed as
treatment-emergent, unless the nonmissing components of the start date conﬁrm other-
wise. A patientwithmore than one TEAEwith the samepreferred term is counted once for
that term.
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however, there were only 3 patients in each treatment group.
4. Discussion
Treatment of epilepsywith AEDsmay impact negatively upon cogni-
tive function, but studies performed in children and adolescents have
been insufﬁcient or inconclusive [15,16,26]. Recent studies based on
appropriate and thorough testing methods have been able to identify
changes in speciﬁc measures of neurocognitive or behavioral function-
ing in pediatric patients with epilepsy in monotherapy or adjunctive
therapy with AEDs [20,27–29]. The present study, designed to evaluate
the effect of ESL when given as add-on therapy on cognitive function of
ESL compared with placebo, in children and adolescents with refractory
FOS over a 12-week double-blind period, is the ﬁrst to evaluate the
effects of ESL on neurocognitive and behavioral functioning, using stan-
dardized and validated tools (CDR system, CHQ-PF50, CBCL, and Raven's
SPM).
Overall, the ﬁndings reported here show that in a 12-week study
period, adjunctive ESL in children and adolescents with FOS mostly
causes nonstatistically signiﬁcant effects on neurocognitive and behav-
ioral functioning. The primary noninferiority analysis failed to reject the
null hypothesis that the change from baseline in the Power of Attention
score in the ESL group was at least 121 ms inferior to the placebo group
for all age groups. However, the primary outcome variable in this study,
Power of Attention, a measure of focused attention, and speed of infor-
mation processing, failed to show a negative effect of ESL; the studywas
adequately powered to detect such an effect (see below). This 121-ms
margin was based on a clinical trial in 12- to 17-year-old adolescentscomparing Power of Attention in newly diagnosed children with
epilepsy with a healthy age-matched normative sample [20]. In the
present study, patients were undergoing treatment with AEDs, and
younger patients (6 to 11 years) were also included. These factors
may have contributed to inferior scores, as indeed seen in the baseline
scores of the study, but also possibly to greater variability. Therefore,
this margin should have included not only the expected difference but
also the variability associated with it, as done in a similar trial where a
healthy normative sample was used as reference [30]. In this regard, it
is of clear relevance that the difference between the two conditions at
the end of the double-blind period was in favor of ESL (see Table 2).
Data from a previous study comparing the effects of two study
treatments (carbamazepine [CBZ] and remacemide) in the 12- to
17-year-old patients from the study have just been published [29]; it
was identiﬁed that after 8 weeks of dosing, a signiﬁcant difference of
107 ms on Power of Attention was detected (P = 0.0059) between
remacemide (n = 30) and CBZ (n = 34). At 48 weeks this difference
had increased to 127 ms (P = 0.0055), with 22 patients in the CBZ
arm and 24 patients in the remacemide arm. In the present study, at
the end of the double-blind period when the comparisons were
performed, 36 patients were on placebo and 66 on ESL. This suggests
that the present study was adequately powered to detect a difference
between placebo and ESL had one existed. The patients then entered a
one-year open-label follow-up after the end of the double-blind period.
Over the year, the patients showed a mean improvement in Power of
Attention of 182 ms (235 ms for the 6- to 11-year-old patients and
144 for the 12- to 16-year-old patients). A cross-sectional year-by-
year change in Power of Attention in a large sample of healthy individ-
uals aged 6 to 17 years (Data onﬁle, the CDR system) indicates that from
6 to 16 years of age the average yearly maturational improvement in
healthy childrenwas 70ms. Thus, in the present study, thematurational
development during the one-year open-label follow-up clearly showed
no evidence of falling behind what would be expected for healthy
children.
The other secondary cognitive domains of the CDR systemwere also
not signiﬁcantly different between placebo and ESL, with the exception
for the Episodic Memory Index, a measure of delayed recognition of
previously presented information, which had a statistically reliable
negative effect in the ESL group. However, ESL did have a statistically
reliable negative effect on the Episodic Memory Index, a measure of
delayed recognition of previously presented information. However,
the two groups had notably different prestudy scores on this measure;
the ESL group being initially superior to placebo, and the effect may
instead have represented “regression to the mean”. In a recent study,
adjunctive perampanel was found to have a negative effect on both
Continuity of Attention and Speed of Memory but a possible beneﬁt
for the Quality of Working Memory [28].
In measures of QOL or emotional and behavioral functioning, no
differences were found between ESL and placebo, as demonstrated by
the similar scores obtained in the CBCL, CHQ-PF50, and Raven's SPM.
In contrast, adjunctive levetiracetam negatively impacted speciﬁc
aspects of behavioral and emotional functioning in children, particularly
the CBCL scores for Aggressive Behavior [27], although neurocognitive
effects of levetiracetamwere no different from placebo using other test-
ing methods [30]. Although an indirect comparison with other studies
suggests that ESL appears to cause less neurocognitive and behavioral
effects than other adjunctive treatments in pediatric patients, head-to-
head studies would be useful to make comparative assessments
between ESL and other AEDs.
In line with previous studies in adults [31–36], ESL in a pediatric
population was demonstrated with a good efﬁcacy in reducing overall
seizure frequency, leading to a signiﬁcantly higher proportion of treat-
ment responders and of seizure-free patients, compared to placebo.
The main secondary efﬁcacy endpoint, standardized seizure frequency
over the maintenance period in the ITT population, showed statistically
signiﬁcant improvement over placebo in the ESL group (P b 0.001). The
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ulation. The results from the analyses of the other efﬁcacy endpoints
in the ITT population, including the proportion of responders during
the maintenance period, percent change from baseline in standardized
seizure frequency, and standardized seizure frequency, are consistent
with the conclusions on the analysis of the main secondary efﬁcacy
endpoint. On the other hand, the better control of seizures by ESL may
be associatedwith the observed overall improvement of neurocognitive
performance. There were no statistically signiﬁcant treatment-by-age
group, treatment-by-sex, or treatment-by-country interactions in the
analysis of standardized seizure frequency during the maintenance
period thus indicating that the treatment effect was consistent in each
age group, sex, and country. The results from the one-year open-label
extension showed a prolonged seizure frequency reduction for patients
already receiving ESL during the double-blind part. The previous
double-blind placebo group experienced a decrease in standardized
seizure frequency during the open-label period, gradually becoming
numerically similar to the previous double-blind ESL group. Median
postbaseline standardized seizure frequencies during the one-year
open-label period were lower in the previous double-blind ESL group
compared with the placebo group at most time points. The previous
double-blind placebo group experienced a decrease in standardized
seizure frequency during the open-label period, gradually becoming
similar to the previous double-blind ESL group. These results indicate
reductions in standardized seizure frequency during the open-label
period compared with baseline, with a greater treatment effect
observed in the ESL group.
During the double-blind part of the study, the most common TEAEs
with an incidence of N3% of patients in the ESL group were vomiting,
diplopia, and somnolence, but these were few overall. Headache was
more frequent in patients receiving placebo compared with those
receiving ESL. The incidences for dizziness and somnolencewere similar
between the placebo and ESL groups. Events of rash (including rash,
rash pruritic, and allergic dermatitis), commonly observed with other
AEDs of this class of drugs, were reported by a few patients in the ESL
groups. No events of hyponatremia were reported. The prevalence of
Serious adverse events (SAEs) was low overall.
As was seen in the double-blind part, the TEAEs reported during the
one-year open-label period thatweremore frequent in the previous ESL
group were vomiting, allergic dermatitis, and diplopia, but these were
infrequent overall. Headache was more frequent in patients receiving
previous placebo compared with those receiving previous ESL. The
incidences for dizziness and somnolence were similar between the
previous double-blind placebo and ESL groups. Skin events were re-
ported by a few patients; all 4 events occurred in patients who received
previous double-blind placebo, and none of the events were considered
related to study drug. No events of hyponatremia were reported. The
prevalence of SAEs was low overall. Tolerability of ESL was suggested
by high study completion rates and low incidences of AEs leading to
discontinuation during double-blind and open-label parts of this
study. The AE proﬁle was consistent with previous data on ESL in adults
[32].
Strengths of this study include thewell-matched study populations –
and their baseline scores – and testing with a very comprehensive neu-
ropsychological battery. Even though well validated, the CBCL and the
CHQ-PF50 are administered to the child's parents or legal guardians,
and rely on their ability to recall and interpret the child's behavior,
potentially leading to bias. Though the relatively short-time duration
of the double-blind assessment described here could be seen as a
limitation of this study, especially in what concerns the efﬁcacy result
conclusions, the efﬁcacy results from the one-year open-label long-
term extension to thistprins study supported the results from the
double-blind phase in those patients who elected to remain on treat-
ment. Furthermore, in the open-label extension, maturational develop-
ment on cognition at least matched, if not exceeded, the expected rate
of development seen in an age-matched cohort from the CDR systemdatabase. One potential limitation was the use of the last observation
carried forward in the open-label part. However, the by-visit analysis
does suggest this is not a limitation.
In conclusion, ESL overall did not produce statistically signiﬁcant
effects on neurocognitive and behavioral functioning in patients with
epilepsy aged 6 to 16 years. Additionally, ESL was effective in reducing
seizure frequency and was well-tolerated.
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